Skip to main content
. 2016 Mar 29;30(7):2570–2579. doi: 10.1096/fj.201600244R

Figure 3.

Figure 3.

Sterol-based LXR agonists activate LXR in the brain and reduce inflammation induced by traumatic brain injury (TBI). A) Gene expression analysis of Abca1 and Abcg1 in brain tissues that were collected from mice treated with LXR agonists for 6 d (n = 6). B) Concentrations of LXR agonists in the plasma and brain from mice that were treated with a single dose of LXR agonists. C) LXR agonists activity profile in SHSY5Y cells. D) ABCA1 mRNA expression in SHSY5Y cells that were treated with 1 μM of different LXR agonists for various times. E) TBI experimental design. Compounds or vehicle were given by oral gavage once daily for 3 d before TBI induction. The final dose was given 15 min after injury induction. Tissues were collected 24 h postinjury (n = 5). F) Gene expression analysis of injured brain tissues. Results are presented as means ± sem (A, B, D), and as means ± sd (C). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.